Clinical reactivity and immunogenicity of hemagglutinin influenza vaccine. I. Clinical reactions, hemagglutination-inhibiting and strain and type-specific complement-fixing antibody responses in subjects aged 3-6, 16-17 and 27-50 years.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000818:Animals; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D003168:Complement Fixation Tests; D004890:Erythema / Q000209:etiology; D005334:Fever / Q000209:etiology; D005455:Fluorescent Antibody Technique; D006168:Guinea Pigs; D006385:Hemagglutination Inhibition Tests; D006389:Hemagglutinins, Viral / Q000009:adverse effects; D006801:Humans; D007106:Immune Sera; D007252:Influenza Vaccines / Q000009:adverse effects; D008875:Middle Aged; D009975:Orthomyxoviridae / Q000276:immunology; D011817:Rabbits; D013552:Swine; D014611:Vaccination / Q000009:adverse effects; D014765:Viral Vaccines
D006389:Hemagglutinins, Viral; D007106:Immune Sera; D007252:Influenza Vaccines; D014765:Viral Vaccines